Image Source: AsiaOne
FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting Laboratory Studies Suggest PneumoBlast™ COVID-19 Cell Therapy Reduces Coagulopathy GlobeNewswire August 12, 2020 HOUSTON, Aug. 12, 2020 (GLOBE NEWSWIRE) -- FibroGenesis, a clinical stage company developing fibroblast based therapeutic solutions for unmet medical needs, announced today new data supporting utilization of its PneumoBlast™ product in treatment of COVID-19. Laboratory experiments comprised of admixing PneumoBlast™ with activated monocyte or endothelial cells demonstrated significant inhibition of tissue factor expression. Tissue factor is the key molecule inducing blood clotting in COVID-19 patients. Monocytes are cells which normally protect the body against pathogens. In the case of COVID-19, monocytes enter the lungs and cause coagulation. Endothelial cells are cells which make up the inside of the blood vessel and regulate substance flow between the bloodstream and surrounding tissues.